+ Filter
Loading...
Custom Services order now ship next day

Anti-VEGFR2 Recombinant Antibody Products

Loading...

Anti-VEGFR2 Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs stands as a global leader in advanced antibody discovery and engineering, proudly offering a superior range of anti-VEGFR2 recombinant antibody products. Meticulously designed for researchers and pharmaceutical developers worldwide, our antibodies deliver unparalleled specificity and exceptional reliability. This empowers groundbreaking studies in angiogenesis-related diseases, from cancer to ocular disorders, and accelerates the crucial path towards novel therapeutic development.

VEGFR2: A Pivotal Target for Anti-Angiogenic Therapy

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), also known as KDR or Flk-1, is the primary receptor mediating VEGF-A's potent pro-angiogenic signals. It is critically involved in physiological blood vessel formation, essential for embryonic development, wound healing, and tissue repair. However, its dysregulated activity profoundly drives pathological angiogenesis, notably fueling tumor growth, nutrient supply, and metastatic spread in various cancers. Moreover, VEGFR2 contributes to conditions like age-related macular degeneration. Given this pivotal role, VEGFR2 is a highly significant target for developing effective anti-cancer therapies and other treatments for angiogenesis-driven diseases.

Alternative Names

KDR; kinase insert domain receptor; FLK1; CD309; VEGFR; VEGFR2; vascular endothelial growth factor receptor 2; soluble VEGFR2; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor; kinase insert domain receptor (a type III receptor tyrosine kinase).

Background

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.

Anti-VEGFR2 rAb Products

Our anti-VEGFR2 recombinant antibody products stand out due to their exceptional purity, high affinity, and lot-to-lot consistency. Produced using advanced recombinant technology, these antibodies offer superior specificity for VEGFR2, minimizing off-target effects and ensuring reliable results in diverse research applications, from basic science to preclinical drug development.

Cat. No. Product Name Target Species Host Species Applications
PABL-743 Human Anti-VEGFR2 Recombinant Antibody (clone 1121B) Human Human IgG WB, IF, FuncS
HPAB-2712LY Mouse Anti-VEGFR2 Recombinant Antibody (HPAB-2712LY) Human Mouse IgG ELISA, Inhib
HPAB-2714LY Mouse Anti-VEGFR2 Recombinant Antibody (clone CBL054) Human Mouse IgG ELISA, Inhib
HPAB-0041LY Human Anti-VEGFR2 Recombinant Antibody (HPAB-0041LY) Human Human IgG1 WB, IF, Block
FAMAB-0367WJ Camel Anti-VEGFR2 Recombinant Antibody (clone V21H4) Human Camelid VHH ELISA, WB, FC

Table 1. Featured anti-VEGFR2 recombinant antibody products at Creative Biolabs.

Creative Quality Control

At Creative Biolabs, quality is our cornerstone. Our anti-VEGFR2 recombinant antibodies undergo rigorous, multi-stage quality control, including precise affinity measurements, specific binding validation against VEGFR2, and functional assays to confirm their biological activity. This meticulous process guarantees superior performance and reproducibility, providing researchers with confidence in their experimental outcomes.

SDS-PAGE analysis. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-VEGFR2 antibody
(Cat# PABL-743, Creative Biolabs).

Customer Reviews

Excellent
Ve***n
Human Anti-VEGFR2 Recombinant Antibody (clone 1121B) (PABL-743)
Creative Biolabs' anti-VEGFR2 recombinant antibody dramatically accelerated our in vitro angiogenesis experiments. Its high specificity and low background noise were truly impressive, allowing us to accurately quantify endothelial cell proliferation and migration. A fantastic product for reliable research.
22/Jan/2025
Excellent
Us***i
Human Anti-VEGFR2 Recombinant Antibody (clone 1121B) (PABL-743)
We've consistently achieved excellent results using Creative Biolabs' anti-VEGFR2 antibody for our immunofluorescence studies. The bright and specific signal enabled precise localization of VEGFR2 expression in cellular compartments, which was critical for our project. Highly recommend for its consistent performance.
15/Feb/2025
Excellent
Ed***i
Mouse Anti-VEGFR2 Recombinant Antibody (HPAB-2713LY) (HPAB-2713LY)
The technical support from Creative Biolabs was invaluable in selecting the optimal anti-VEGFR2 product for our complex in vivo studies. The antibody worked exactly as predicted, providing the critical data required to further our therapeutic research. Exceptional product and service!
10/May/2025

rAb Production

Our anti-VEGFR2 recombinant antibodies are manufactured in state-of-the-art facilities using a proprietary mammalian expression system. This stringent production process ensures high yield, exceptional purity, and batch-to-batch consistency, delivering a reliable supply of premium-grade antibodies for your research demands.

Featured Anti-VEGFR2 Recombinant Antibody Production PlatformsMilligram-scale. (Creative Biolabs Original)
Fig.2 Milligram-scale anti-VEGFR2 recombinant antibody production.

Gram-scale. (Creative Biolabs Original)Fig.3 Gram-scale anti-VEGFR2 recombinant antibody production.

rAb Modalities

Creative Biolabs offers anti-VEGFR2 recombinant antibodies in multiple modalities, including monoclonal, polyclonal, and various engineered formats, providing versatile tools for a wide array of research and therapeutic development applications.

VEGFR2 antibody production and modalities. (Creative Biolabs Original)Fig.4 Full-length anti-VEGFR2 recombinant antibody production and modalities.

VEGFR2-Targeted Drug Information

Company Research phase Classification Condition
GeneScience Pharmaceuticals (Originator) Phase III Cancer Immunotherapy
Chimeric Monoclonal Antibodies
Cancer, gastroesophageal junction
Cancer, gastrointestinal
Cancer, lung (non-small cell) (NSCLC)
Cancer, lung (non-small cell) (NSCLC), metastatic
Cancer, solid tumor
3SBio
PharmAbcine (Originator)
Phase II Cancer Immunotherapy
Human Monoclonal Antibodies
Cancer
Cancer, solid tumor
Glioblastoma multiforme
Triple negative breast cancer
Merck KGaA
Scripps Research (Originator)
VAXIMM
Phase I/II Cancer Immunotherapy
Cancer Vaccines
Recombinant Vector Vaccines
Astrocytoma
Cancer
Cancer, colorectal
Cancer, colorectal, metastatic
Cancer, pancreas
Glioblastoma
Glioma
National Cancer Institute (Originator)
National Cancer Institute (NCI) (National Cancer Institute)
Phase I/II Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Cancer, metastatic
Pfizer (Originator) Discontinued Cancer Immunotherapy
Humanized Monoclonal Antibodies
Cancer, solid tumor
Uppsala Universitet (UU) (Originator) Preclinical Affibodies
Nuclear Imaging Agents
Polypeptides, from 41 AA
Radiopharmaceuticals
Recombinant proteins
Glioma
National Health Research Institutes (Originator) Preclinical Fc Fusion Proteins
Polypeptides, from 41 AA
Vascular Endothelial Growth Factors (VEGF)
Cancer
Melanoma
Istituto Dermopatico Dell'Immacolata (Originator)
Universita degli Studi Roma Tor Vergata (Originator)
Preclinical Cancer Immunotherapy
Murine Monoclonal Antibodies
Cancer
First Affiliated Hospital Anhui Med Univ (Originator) Preclinical Short Hairpin RNA (shRNA) Cancer, liver (hepatocellular carcinoma)
Beth Israel Deaconess Medical Center (Originator)
University of Massachusetts (Originator)
Preclinical Double-stranded oligoribonucleotide (RNA)
Small Interfering RNA (SiRNAs)
Pre-eclampsia
University of Colorado (Originator) Preclinical Monoclonal Antibodies Dysplasia, bronchopulmonary
Lilly (Originator) Preclinical Bispecific Antibodies
Cancer Immunotherapy
Monoclonal Antibodies
Single-Chain V-Domain Antibody Fragment (scFv)
Cancer

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Table 2. Public drug targeting VEGFR2.

Boost your study with the state-of-the-art anti-VEGFR2 recombinant antibody products from Creative Biolabs. We invite you to explore the full potential of these highly validated reagents, designed to provide the precision and reliability your critical experiments demand. To learn more about our comprehensive offerings, discuss specific product specifications, or explore custom antibody development services tailored to your unique project needs, please do not hesitate to contact our expert team. We are dedicated to supporting your scientific breakthroughs and accelerating your path to discovery.

Go to compare

Go to compare

Merry Christmas & Happy New Year
Happy Thanksgiving close ad